| Schedule of changes in the transaction price. |
| | | | | | | | | | | | | | | | | | December 31,
2023 | | Other
movements
in 2024 | | December 31,
2024 | | Other
movements
in 2025 | | December 31,
2025 | | | | (Euro, in thousands) | Upfront consideration | | € | 4,018,016 | | | | | € | 4,018,016 | | | | | € | 4,018,016 | Milestones achieved | | | 212,601 | | | | | | 212,601 | | | | | | 212,601 | Royalties | | | 40,176 | | € | 10,604 | | | 50,780 | | € | 12,177 | | | 62,957 | Impact initial valuation of share subscription | | | 124,604 | | | | | | 124,604 | | | | | | 124,604 | | | | 4,395,397 | | | 10,604 | | | 4,406,001 | | | 12,177 | | | 4,418,178 | Less: | | | | | | | | | | | | | | | | Warrants issuance liabilities | | | | | | | | | | | | | | | | Warrant A | | | (43,311) | | | | | | (43,311) | | | | | | (43,311) | Initial Warrant B | | | (2,545) | | | | | | (2,545) | | | | | | (2,545) | Subsequent Warrant B | | | (54) | | | 45 | | | (9) | | | | | | (9) | | | | 4,349,487 | | | 10,649 | | | 4,360,136 | | | 12,177 | | | 4,372,313 | Allocation to performance obligations | | | | | | | | | | | | | | | | Ziritaxestat | | | 666,967 | | | | | | 666,967 | | | | | | 666,967 | Filgotinib (1) | | | 1,381,644 | | | 10,604 | | | 1,392,248 | | | 12,177 | | | 1,404,425 | Drug discovery platform | | € | 2,300,876 | | € | 45 | | € | 2,300,921 | | € | | | € | 2,300,921 | | | | | | | | | | | | | | | | |
|